These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19069365)

  • 1. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report.
    Duconge J; Cadilla CL; Renta JY; Silén-Rivera P; Piovanetti P; García-Berdecía R; Castro-Rosario LM; Monzón S; Vélez L; Rosas G; Guerra JA; Santiago-Borrero PJ
    P R Health Sci J; 2008 Dec; 27(4):357-8. PubMed ID: 19069365
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2C19*2 and CYP2C19*3 allelomorphism in Turkish population.
    Dogan A
    Int J Cardiol; 2017 Jul; 239():12. PubMed ID: 28560959
    [No Abstract]   [Full Text] [Related]  

  • 3. Voriconazole toxicity related to polymorphisms in CYP2C19.
    Suan D; O'Connor K; Booth DR; Liddle C; Stewart GJ
    Intern Med J; 2011 Apr; 41(4):364-5. PubMed ID: 21507170
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Miao J; Liu R; Li Z
    N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis.
    Bozdag G; Alp A; Saribas Z; Tuncer S; Aksu T; Gurgan T
    Reprod Biomed Online; 2010 Feb; 20(2):286-90. PubMed ID: 20113968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.
    Hirota T; Eguchi S; Ieiri I
    Drug Metab Pharmacokinet; 2013; 28(1):28-37. PubMed ID: 23165865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans?
    Helsby N; Goldthorpe M; Gow P; de Zoysa J
    N Z Med J; 2010 May; 123(1315):37-41. PubMed ID: 20581929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.
    Yang ZF; Cui HW; Hasi T; Jia SQ; Gong ML; Su XL
    Genet Mol Res; 2010 Sep; 9(3):1844-51. PubMed ID: 20845310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.
    Allabi AC; Gala JL; Desager JP; Heusterspreute M; Horsmans Y
    Br J Clin Pharmacol; 2003 Dec; 56(6):653-7. PubMed ID: 14616425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury.
    Srinivas NR
    Aliment Pharmacol Ther; 2017 Oct; 46(7):706-707. PubMed ID: 28880446
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population.
    Hu LM; Dai DP; Hu GX; Yang JF; Xu RA; Yang LP; Qian JC; Ge RS; Cai JP
    Pharmacogenomics; 2012 Nov; 13(14):1571-81. PubMed ID: 23148634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture.
    Castro de Guerra D; Flores S; Izaguirre MH
    Ann Hum Biol; 2013 Mar; 40(2):197-200. PubMed ID: 23249123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
    Klotz U
    Eur J Clin Pharmacol; 2009 Jan; 65(1):1-2. PubMed ID: 18958459
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments.
    Serrano D; Torrado S; Torrado-Santiago S; Gisbert JP
    Curr Drug Metab; 2012 Nov; 13(9):1303-12. PubMed ID: 22493986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CYP2C19 polymorphisms in patients with endometriosis.
    Cayan F; Ayaz L; Aban M; Dilek S; Gümüş LT
    Gynecol Endocrinol; 2009 Aug; 25(8):530-5. PubMed ID: 19499406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
    Burger DM; Schwietert HR; Colbers EP; Becker M
    Br J Clin Pharmacol; 2006 Aug; 62(2):250-2. PubMed ID: 16842404
    [No Abstract]   [Full Text] [Related]  

  • 20. [Genetic polymorphism of CYP-450 in drug development].
    Nonen S; Azuma J
    Nihon Yakurigaku Zasshi; 2009 Oct; 134(4):212-5. PubMed ID: 19828926
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.